 |
32 Diseases |  |
5 Trials |
|
5 Trials |  |
1782 News |  |
| «12345678910111213...1314» |
- Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, glecaprevir (ABT-493) / AbbVie, Daklinza (daclatasvir) / BMS
Hard-to-Treat HCV - An Approach to Retreatment With Extended Duration: A Case Report (Crown Ballroom) - Sep 4, 2022 - Abstract #ACG2022ACG_1810;
We then elected to initiate a protracted course of antiviral therapy SOF/daclatasvir followed by SOF/velpatasvir (SOF/VEL), SOF/G/P, and SOF/VEL for a total duration of 56 weeks...Our patient despite a history of failing to achieve SVR, was finally able to achieve SVR12 after roughly 13 months of continuous DAAs coupled with RBV and IFN as tolerated. It is possible, therefore, that extending treatment length beyond current recommendations may be necessary to successfully induce a durable response among patients with multiple RASs and previous treatment failures.
- A Hepatitis C (HCV) Infection Treatment Dilemma (Crown Ballroom) - Sep 4, 2022 - Abstract #ACG2022ACG_592;
Patient was instructed to start the ezetimibe with the GLE/PIB + SOF but was hesitant to take it due to adverse reaction to statins in the past...HCV relies on cell-to-cell transmission, so we chose to add ezetimibe 10mg daily until HCV not detected. There is a need for larger studies to determine the applicability of this case study to other patients.
- | Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
Journal: Dual versus triple therapy in treatment of hepatitis C virus (HCV). (Pubmed Central) - Aug 31, 2022
Although group D patients initially had poor pretreatment investigations relative to other groups, they proved to have the highest tolerability to this regimen. Such findings hold promising line of treatment and better prognosis even for chronic HCV patients with poor liver condition.
- | velpatasvir (GS-5816) / Gilead, Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
Journal: First report in Peru on direct-acting antiviral therapy for chronic hepatitis C in HIV-positive patients (Pubmed Central) - Aug 4, 2022
This present investigation is the first clinical experience in Peru with DAAs for chronic hepatitis C in HIV-positive patients. Virologic response, tolerability, and safety against daclatasvir and velpatasvir, each in conjunction or in combination with sofosbuvir, were optimal in the case series presented.
- | Sunvepra (asunaprevir) / BMS, Daklinza (daclatasvir) / BMS
Journal: Analysis of direct-acting antiviral-resistant hepatitis C virus haplotype diversity by single-molecule and long-read sequencing. (Pubmed Central) - Jun 29, 2022
The combination of various mutations other than the known signature RAS was suggested to influence the kinetics of individual HCV quasispecies in the direct-acting antiviral treatment. HCV haplotype dynamic analysis will provide novel information on the role of HCV diversity within the host, which will be useful for elucidating the pathological mechanism of HCV-related diseases.
- | Trial completion: GEHEP: Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions (clinicaltrials.gov) - Jun 29, 2022
P=N/A, N=1128, Completed, Sponsor: Valme University Hospital
HCV haplotype dynamic analysis will provide novel information on the role of HCV diversity within the host, which will be useful for elucidating the pathological mechanism of HCV-related diseases. Unknown status --> Completed
- | Daklinza (daclatasvir) / BMS
Journal, Combination therapy: Synergistic inhibition of hepatitis C virus infection by a novel microtubule inhibitor in combination with daclatasvir. (Pubmed Central) - Jun 4, 2022
In addition, the combination responses of microtubule inhibitors with daclatasvir, which is a clinically used HCV NS5A inhibitor, were also evaluated. Our results indicated that microtubule targeting had activity against HCV replication and showed synergistic effect with a current clinical drug.
- | Journal: Assessing the Risk of Decrease in Kidney Function in Patients Prescribed Direct-Acting Antivirals for Hepatitis C Utilizing the MID-NET Medical Information Database Network in Japan. (Pubmed Central) - May 31, 2022
Among the 10 patterns, a significant increase in the incidence rate ratio (P < 0.01) was observed in the prescription patterns of concomitant use of telaprevir with peginterferon alpha and ribavirin, concomitant use of daclatasvir hydrochloride with asunaprevir, and ombitasvir hydrate combined with paritaprevir hydrate and ritonavir, which were concomitantly used with ribavirin; such an increase was not observed in the other prescription patterns. The effects of DAAs on kidney function may differ among drugs, suggesting the possibility that the risk of kidney disease is not a class effect of DAAs and should be evaluated individually for each DAA.
- | Sunvepra (asunaprevir) / BMS, Daklinza (daclatasvir) / BMS
Enrollment change, Trial withdrawal: Early Post-marketing Study of Daclatasvir (Daklinza (clinicaltrials.gov) - May 27, 2022
P=N/A, N=0, Withdrawn, Sponsor: Bristol-Myers Squibb
The effects of DAAs on kidney function may differ among drugs, suggesting the possibility that the risk of kidney disease is not a class effect of DAAs and should be evaluated individually for each DAA. N=30 --> 0 | Not yet recruiting --> Withdrawn
- | Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead
Journal: Safety and efficacy of sofosbuvir-velpatasvir-voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial. (Pubmed Central) - May 18, 2022
P4
A 12 week course of sofosbuvir-velpatasvir-voxilaprevir is safe and efficacious for the re-treatment of individuals infected with HCV genotype 4 non-a/d subtypes with frequent baseline NS5A resistance-associated substitutions, following failure of previous direct-acting antiviral treatment. Improved affordability and access to sofosbuvir-velpatasvir-voxilaprevir in regions with these subtypes is crucial.
- || Daklinza (daclatasvir) / BMS
P2 data, Journal: Efficacy and safety of alfosbuvir plus daclatasvir in Chinese patients with hepatitis C virus genotypes 1, 2, 3, and 6 infection - an open-label, phase 2 study. (Pubmed Central) - May 15, 2022
P2/3
There were no discontinuations due to adverse events, and no treatment-related serious adverse events were reported. Once-daily oral administration of alfosbuvir plus daclatasvir were highly effective and safe in Chinese patients infected with HCV genotype 1, 2, 3, or 6, suggesting this regimen could be a promising drug candidate for HCV treatment irrespective of genotype.
- Daklinza (daclatasvir) / BMS, Tivicay (dolutegravir) / ViiV Healthcare
Quantifying the health and economic impact of voluntary licensing of HIV medicines in low- and middle-income countries: putting numbers on additional uptake, deaths averted, and money saved by MPP licences (Room 516/Channel 6) - May 12, 2022 - Abstract #AIDS2022AIDS_483;
Results for atazanavir (ATV), DTG (now also for paediatric use), lopinavir/ritonavir (LPV/r), and tenofovir disoproxil fumarate (TDF), together representing > 95% of MPP impact so far, are presented... Modelling the impact of MPP licences for HIV medicines offers visibility on the overall contribution to the global HIV response of the MPP model of public-health oriented voluntary licensing and a means to assess the investment (additional expenditure) that would be needed for the same level of optimal drug uptake without MPP licences: 22 billion USD in cumulative theoretical expenditures avoided by 2030.
- | Daklinza (daclatasvir) / BMS
Journal: Changes in Serum Interferon Gamma and Interleukin-10 in Relation to Direct-Acting Antiviral Therapy of Chronic Hepatitis C Genotype 4: A Pilot Study. (Pubmed Central) - May 12, 2022
IFN-γ and IL-10 showed different correlations with laboratory markers. Viral eradication induced by DAAs caused a significant change in IL-10 and IFN-gamma.
- Zepatier (grazoprevir/elbasvir) / Merck (MSD), Daklinza (daclatasvir) / BMS, Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Eliminating hepatitis C virus infection in prisons: 7 years of experience (Poster Area) - May 12, 2022 - Abstract #EASLILC2022EASL_ILC_1941;
All the 79 patients were initially treated with Sofosbuvir/Ledipasvir and Daclatasvir with or without ribavirin (according to criteria defined in initial protocols) and more recently, Grazoprevir/Elbasvir and pangenotypic drugs, namely Sofosbuvir/Velpatasvir, and Glecaprevir/Pibrentasvir. Our encouraging data is a result from an optimized partnership between the healthcare team in prisons and our hospital, allowing a fast diagnosis, an agile disease staging and adequate treatment, minimizing future risk of transmission and taking us closer to eliminating the infection by 2030.
- || Daklinza (daclatasvir) / BMS
Clinical, Journal: Real-life experience of treating HCV co-infection among HIV-infected population in Egypt: single-center experience. (Pubmed Central) - May 6, 2022
DAAs are an effective and safe choice to treat HCV in PLHIV. Social stigma could be a major cause for lacking adherence to follow-up visits.Abbreviations: ALT: Alanine Aminotransferase; ARV: Antiretroviral treatment; AST: Aspartate Aminotransferase; DAAs: Direct acting antivirals; ARVs: antiretroviral therapy; EMR: Eastern Mediterranean region; HCV: Hepatitis C virus; kPa: Kilopascal; LTFU: Patient lost to follow up; NCCVH: The National Committee for Control of Viral Hepatitis; PWID: People who inject drugs; SVR: Sustained virological response;UNAIDS: The Joint United Nations Programme on HIV/AIDS.
- | Preclinical, Journal: In Vitro Assessment of Transporter Mediated Perpetrator DDIs for Several Hepatitis C Virus Direct-Acting Antiviral Drugs and Prediction of DDIs with Statins Using Static Models. (Pubmed Central) - May 6, 2022
Inhibitory effects of asunaprevir, daclatasvir, grazoprevir, paritaprevir, simeprevir, and voxilaprevir, direct-acting antiviral (DAA) drugs for the treatment of chronic hepatitis C virus (HCV) infection, were evaluated in vitro against a range of clinically important drug transporters...Furthermore, we refined and developed static models to predict complex DDIs with several statins (pitavastatin, rosuvastatin, atorvastatin, and pravastatin) by mechanistically assessing differential inhibitory effects of perpetrator drugs on multiple transporters, such as organic anion transporting polypeptides (OATP1B), breast cancer resistance protein (BCRP), multidrug resistance protein 2 (MRP2), organic anion transporter 3 (OAT3), and cytochrome P450 CYP3A enzyme, as they are known to contribute to absorption, distribution, metabolism and excretion (ADME) of above statins...Our studies suggest that mechanistic static model is a promising and useful tool to provide more accurate prediction of the risk and magnitude of DDIs with statins in early drug development and may help to improve the management of clinical DDIs for HCV drugs to ensure effective and safe HCV therapy. GRAPHICAL ABSTRACT.
- | Daklinza (daclatasvir) / BMS
Journal: Possible Alterations in Appetite-related Molecules After the Elimination of Hepatitis C Virus. (Pubmed Central) - May 5, 2022
GRAPHICAL ABSTRACT. Gastrointestinal hormones related to the dietary habit and/or appetite may be influenced by HCV elimination.
- | Journal: Computational estimation of potential inhibitors from known drugs against the main protease of SARS-CoV-2. (Pubmed Central) - Apr 29, 2022
Among them, the seven top leads are daclatasvir, teniposide, etoposide, levoleucovorin, naldemedine, cabozantinib, and irinotecan. The potential application of these drugs in COVID-19 therapy has thus been discussed.
- sofosbuvir/velpatasvir / Generic mfg.
EFFICACY AND SAFETY OF PAN-GENOTYPIC SOFOSBUVIR AND VELPATASVIR IN PATIENTS WITH HEPATITIS C REINFECTION FOLLOWING ATTAINMENT OF SUSTAINED VIROLOGICAL RESPONSE WITH NS5A INHIBITORS (Poster Hall - San Diego Convention Center) - Apr 25, 2022 - Abstract #DDW2022DDW_951;
No grade III/IV adverse events were observed. Conclusion :Treatment with the pan-genotypic combination of Sofosbuvir and Velpatasvir is highly effective and safe in patients with HCV reinfection.
- | Ledipasvir (GS-5885) / Gilead, Daklinza (daclatasvir) / BMS
Journal: A clinical and molecular epidemiological survey of hepatitis C in Blantyre, Malawi suggests an historic mechanism of transmission. (Pubmed Central) - Apr 22, 2022
HCV infection was observed only among older people, suggesting an historic mechanism of transmission. Genotype 4r, which has been associated with treatment failure with ledipasvir and daclatasvir, is endemic.
- | pibrentasvir (ABT-530) / AbbVie, velpatasvir (GS-5816) / Gilead, Daklinza (daclatasvir) / BMS
Journal: Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals. (Pubmed Central) - Apr 19, 2022
Older patients and patients with advanced liver diseases are more likely to select drug-resistant viruses. Collective efforts from international communities and governments are needed to develop an optimal approach to managing drug resistance and preventing the transmission of resistant viruses.
- | Daklinza (daclatasvir) / BMS
Journal, Real-world evidence: Hepatitis C Virus Treatment Response to Direct-acting Antivirals Among Adolescents With HIV/HCV Coinfection: Real-world Data From Ukraine. (Pubmed Central) - Apr 15, 2022
All 6 patients achieved sustained virologic response by 12 weeks after the end of therapy. DAA treatment was well tolerated and effective in adolescents with HIV/HCV coinfection in a real-world setting.
- | ivermectin oral / Generic mfg.
Journal: Identification of host transcriptome-guided repurposable drugs for SARS-CoV-1 infections and their validation with SARS-CoV-2 infections by using the integrated bioinformatics approaches. (Pubmed Central) - Apr 15, 2022
We also detected some chemicals (Valproic Acid, Cyclosporine, Copper Sulfate and arsenic trioxide) that may regulates HubGs...We found Rapamycin, Tacrolimus, Torin-2, Radotinib, Danoprevir, Ivermectin and Daclatasvir as the top-ranked 7 candidate-drugs with respect to our proposed target proteins for the treatment against SARS-CoV-1 infections...Finally, we validated all of our findings by the literature review. Therefore, the proposed candidate-drugs might play a vital role for the treatment against different variants of SARS-CoV-2 infections with comorbidities, since the proposed HubGs are also associated with several comorbidities.
- || Zepatier (grazoprevir/elbasvir) / Merck (MSD), Daklinza (daclatasvir) / BMS
Clinical, Journal, Real-world evidence: Real-world efficacy and safety of direct-acting antiviral drugs in patients with chronic hepatitis C and inherited blood disorders. (Pubmed Central) - Apr 12, 2022
DAA-based regimens are well tolerated and highly efficacious in patients with chronic hepatitis C and IBLD in the real-world setting. Thus, DAA-based antiviral treatment should be prioritized in this thus far neglected population of HCV-infected patients.
- || Daklinza (daclatasvir) / BMS
Clinical, Journal: Changes in serum interferon-γ-inducible protein-10 levels and liver stiffness among chronic hepatitis C Egyptian patients in response to directly acting antiviral agents. (Pubmed Central) - Apr 12, 2022
IP-10 significant decline post-DAAs treatment in chronic HCV genotype IV infected patients reflects significant improvement in fibrosis stage and hepatic necro-inflammation in response to treatment. No significant correlation was detected in the changes of both IP-10 and LSM.
- || grazoprevir (MK-5172) / Merck (MSD), Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
Review, Journal: Antivirals against HCV infection: the story thus far. (Pubmed Central) - Apr 1, 2022
Despite these milestones, the WHO global target of eliminating hepatitis C as a public health problem by 2030 seems uncertain. In this review, we provide a concise account of the evolution and advancements in the development of anti-HCV regimens.
- | Daklinza (daclatasvir) / BMS
Journal: Factors Influencing the Intracellular Concentrations of the Sofosbuvir Metabolite GS-331007 (in PBMCs) at 30 Days of Therapy. (Pubmed Central) - Mar 27, 2022
The aim of this study was to investigate whether clinical and pharmacological factors could influence GS-331007 intracellular (IC) concentrations in peripheral blood mononuclear cells (PBMCs) associated with a sustained virological response in patients treated with SOF and ribavirin (RBV)...The GS-331007 IC concentration at 30 days was associated with its plasma concentration determinate at 30, 60 and 90 days of SOF-therapy and with daclatasvir concentrations at 7 days of therapy...This study presents data on an IC evaluation in a cohort of patients treated with SOF, also considering pharmacogenetics. These results could be useful for regions where SOF-RBV treatment is considered the standard of care; moreover, they could further deepen the knowledge of IC exposure for similar drugs in the future.
- | Daklinza (daclatasvir) / BMS
Biomarker, Journal: Computational identification of host genomic biomarkers highlighting their functions, pathways and regulators that influence SARS-CoV-2 infections and drug repurposing. (Pubmed Central) - Mar 22, 2022
We found Torin-2, Rapamycin, Radotinib, Ivermectin, Thiostrepton, Tacrolimus and Daclatasvir as the top ranked seven candidate drugs...Finally, we investigated the stability of top three drugs (Torin-2, Rapamycin and Radotinib) by using 100 ns MD-based MM-PBSA simulations with the two top-ranked proposed receptors (TLR2, USP53) and independent receptors (IRF7, STAT1), and observed their stable performance. Therefore, the proposed drugs might play a vital role for the treatment against different variants of SARS-CoV-2 infections.
- || Daklinza (daclatasvir) / BMS
Clinical, Journal: Treatment of hepatitis C virus infection with direct-acting antiviral agent-based regimens in Iranian patients with hereditary bleeding disorders. (Pubmed Central) - Mar 12, 2022
Therefore, the proposed drugs might play a vital role for the treatment against different variants of SARS-CoV-2 infections. Hepatitis C DAA-based regimens are the effective treatments for CHC in patients with HBD, regardless of the treatment modifiers such as previous treatment experience, cirrhosis, HIV co-infection, and HCV genotype.
- | Daklinza (daclatasvir) / BMS
Preclinical, Journal: Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay. (Pubmed Central) - Mar 5, 2022
Thus, we provide methods for rapid and effective screening and development of inhibitors for blocking virus polyprotein processing as SARS-CoV-2 antivirals. Additionally, we show that the combined inhibition of Mpro and PLpro is more effective in inhibiting SARS-CoV-2 and the delta variant.
- | Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: REVOLUTIOn: Antiviral Agents Against COVID-19 Infection (clinicaltrials.gov) - Feb 28, 2022
P2/3, N=256, Active, not recruiting, Sponsor: Hospital do Coracao
Additionally, we show that the combined inhibition of Mpro and PLpro is more effective in inhibiting SARS-CoV-2 and the delta variant. Recruiting --> Active, not recruiting | N=1005 --> 256 | Trial completion date: Feb 2022 --> Dec 2022 | Trial primary completion date: Nov 2021 --> Aug 2021
- | Preclinical, Journal: Evaluation of the Potency of Anti-HIV and Anti-HCV Drugs to Inhibit P-Glycoprotein Mediated Efflux of Digoxin in Caco-2 Cell Line and Human Precision-Cut Intestinal Slices. (Pubmed Central) - Feb 27, 2022
However, abacavir, dolutegravir, maraviroc, sofosbuvir, tenofovir disoproxil fumarate, and zidovudine had no inhibitory effect...More inhibitors were identified when using digoxin as the ABCB1 probe substrate than when using rhodamine123. However, both approaches had limitations, indicating that inhibitory potency should be tested with at least these two ABCB1 probes.
- || velpatasvir (GS-5816) / Gilead, Daklinza (daclatasvir) / BMS
Clinical, Journal: Sofosbuvir-based antiviral therapy provided highly treatment efficacy, safety and good tolerability for Taiwanese chronic hepatitis C patients with decompensated cirrhosis. (Pubmed Central) - Feb 26, 2022
However, both approaches had limitations, indicating that inhibitory potency should be tested with at least these two ABCB1 probes. For patients with HCV-related decompensated cirrhosis, which has been considered a contraindication for interferon-based therapy, sofosbuvir-based all-oral DAAs provided high treatment efficacy, acceptable safety, and good tolerability.
- | Daklinza (daclatasvir) / BMS
Journal: Treatment and monitoring of children and adolescents with hepatitis C in Russia: Results from a multi-centre survey on policy and practice. (Pubmed Central) - Feb 25, 2022
This study provides a baseline of DAA uptake in early stages of rollout for children and adolescents. The use of DAAs for treatment of adolescents in Russia presents a unique opportunity for HCV micro-elimination in this population.
- ||| Trial completion, Enrollment change, Real-world evidence, Adverse drug reaction, Real-world: Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving Daclatasvir (DCV) Trio Therapy (clinicaltrials.gov) - Feb 23, 2022
P=N/A, N=344, Completed, Sponsor: Bristol-Myers Squibb
The use of DAAs for treatment of adolescents in Russia presents a unique opportunity for HCV micro-elimination in this population. Active, not recruiting --> Completed | N=1000 --> 344
- | Daklinza (daclatasvir) / BMS
Journal: Dibenzo-18-Crown-6-based Carbon Paste Sensors for the Nanomolar Potentiometric Determination of Daclatasvir Dihydrochloride: An Anti-HCV Drug and a Potential Candidate for Treatment of SARS-CoV-2. (Pubmed Central) - Feb 17, 2022
A selectivity study was performed, and the proposed sensors exhibited good discrimination between DAC and potentially coexisting interferents with sensor II displaying better selectivity. Finally, sensor II was successfully applied for the determination of DAC in the above-mentioned samples, with recovery values ranging from 99.25 to 101.42%, and relative standard deviation (RSD) values ranging from 0.79 to 1.53% which reflected the high accuracy and precision.
- | Daklinza (daclatasvir) / BMS
Preclinical, Journal: Influence of Piperine and Omeprazole on The Regional Absorption of Daclatasvir from Rabbit Intestine. (Pubmed Central) - Feb 16, 2022
This effect was inhibited by piperine. Co-administration of daclatasvir with omeprazole can enhance intestinal absorption a phenomenon which requires extension to human pharmacokinetic investigation.
- | Daklinza (daclatasvir) / BMS
Journal: The economic and public health impact of intellectual property licensing of medicines for low-income and middle-income countries: a modelling study. (Pubmed Central) - Feb 15, 2022
The chain of effects linking upstream licensing to downstream outcomes can be modelled. Accordingly, credible quantitative estimates of economic and health effects arising from access-oriented voluntary licensing were obtained based on assumptions that early generic competition leads to price reductions that influence procurement decisions and enable the faster and broader uptake of recommended medicines, with beneficial economic and health effects.
- | Daklinza (daclatasvir) / BMS
Journal: Redesigning of the cap conformation and symmetry of the diphenylethyne core to yield highly potent pan-genotypic NS5A inhibitors with high potency and high resistance barrier. (Pubmed Central) - Feb 8, 2022
Compound 15, a symmetrically m-, m'-substituted diphenyl ethyne analog, was 150-fold more potent than daclatasvir against GT 3a, while compound 33, an asymmetrically m-, p-substituted diphenyl ethyne analog, was 35-fold more potent than daclatasvir against GT 3a. In addition, compound 15 exhibited a higher resistance barrier than daclatasvir against genotype 1b.
- | Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
Journal: Direct Relationship between Interleukin-10 Gene Polymorphism and Hepatocellular Carcinoma Complicated by Direct Acting Antiviral Treatment of Hepatitis C Virus. (Pubmed Central) - Feb 5, 2022
In addition, compound 15 exhibited a higher resistance barrier than daclatasvir against genotype 1b. IL-10 genotyping may help in selecting the safest and most accurate drug regimen according to the safest genotype response relationship and follow-up of genotype resistance.
- | Daklinza (daclatasvir) / BMS
Journal: RP-HPLC method development and validation for quantification of daclatasvir dihydrochloride and its application to pharmaceutical dosage form. (Pubmed Central) - Feb 1, 2022
The method was successfully applied to the assay and in-vitro dissolution studies of daclatasvir dihydrochloride in tablet dosage form. It can be concluded that this method can be very helpful in the quality control estimation of daclatasvir dihydrochloride in different pharmaceutical products intended for hepatitis C infections.
- | velpatasvir (GS-5816) / Gilead, Ledipasvir (GS-5885) / Gilead, Daklinza (daclatasvir) / BMS
Journal: Sugaring-out induced homogeneous liquid-liquid microextraction as an alternative mode for biological sample preparation, a comparative study. (Pubmed Central) - Jan 27, 2022
These results shows that sugaring-out induced liquid-liquid microextraction could be a more efficient microextraction mode for preparation of biological samples. Compared with other types of microextraction, sugaring-out induced liquid-liquid microextraction is greener, simpler, and cost-effective, with less tendency to affect the sample pH.
- || Daklinza (daclatasvir) / BMS
Clinical, Journal: Effective and Safe Daclatasvir Drug Exposures Predicted in Children Using Adult Formulations. (Pubmed Central) - Jan 19, 2022
These results should be validated clinically. Low-cost available adult DCV formulations together with approved pediatric doses of SOF would expand global access to HCV treatment for children.
- | Daklinza (daclatasvir) / BMS
Journal: Evaluation of the Binding Affinity of Anti-Viral Drugs against Main Protease of SARS-CoV-2 through a Molecular Docking Study. (Pubmed Central) - Jan 18, 2022
Low-cost available adult DCV formulations together with approved pediatric doses of SOF would expand global access to HCV treatment for children. In conclusion, protease inhibitors may be effective potential antiviral agents against Mpro to combat SARSCoV-2.
- || Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients. (Pubmed Central) - Jan 15, 2022
In conclusion, these data suggest that the two SNPs have the potential in predicting the response rate to SOF/DCV treatment in patients infected with HCV GT4. This study is the first to investigate the pharmacogenetics of SOF metabolizing enzyme and introduce HINT1 rs7728773 as a novel SNP that predict the treatment efficacy.
- || pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie, Daklinza (daclatasvir) / BMS
Retrospective data, Review, Journal, Real-world evidence: Real-World Effectiveness of Direct-Acting Antiviral Regimens against Hepatitis C Virus (HCV) Genotype 3 Infection: A Systematic Review and Meta-Analysis. (Pubmed Central) - Jan 14, 2022
The SVR rate of GLE + PIB was higher than other regimens. SOF + VEL + VOX can be used as a treatment regimen following DAA treatment failure.
- || Sunvepra (asunaprevir) / BMS, Daklinza (daclatasvir) / BMS
Biomarker, Clinical, Journal: EXPRESS: Serum GP88 as a predictive biomarker for hepatocellular carcinoma in patients with viral hepatitis C after direct-acting antiviral agents. (Pubmed Central) - Jan 14, 2022
SOF + VEL + VOX can be used as a treatment regimen following DAA treatment failure. Sustained high levels of sGP88 in patients treated with DAA agents are correlated with the risk of developing HCC.
- | Daklinza (daclatasvir) / BMS
Journal: Structural characterization of methyl-β-cyclodextrins by high-performance liquid chromatography and nuclear magnetic resonance spectroscopy and effect of their isomeric composition on the capillary electrophoresis enantioseparation of daclatasvir. (Pubmed Central) - Jan 12, 2022
The study indicated the importance of the type and composition of derivatized CDs on chiral separations in capillary electrophoresis as well as the importance of proper quality control for cyclodextrin manufacturers. Moreover, the observed migration order could be rationalized based on the composition and substitution pattern of the CDs.
- || Elpida (elsulfavirine) / Viriom
Trial completion: Study to Evaluate the Safety and PK of Elpida (clinicaltrials.gov) - Jan 11, 2022
P1, N=36, Completed, Sponsor: Viriom
Moreover, the observed migration order could be rationalized based on the composition and substitution pattern of the CDs. Recruiting --> Completed
- | Daklinza (daclatasvir) / BMS
Journal: The compound SBI-0090799 inhibits Zika virus (ZIKV) infection by blocking de novo formation of the membranous replication compartment. (Pubmed Central) - Dec 28, 2021
Intriguingly, this defines a novel non-enzymatic target and chemical matter for the development of a new class of ZIKV antivirals. Moreover, chemical modulation affecting this non-structural protein mirrors the identification and development of hepatitis C virus (HCV) NS5A inhibitor daclatasvir and its derivatives, similarly interfering with the formation of the viral replication compartment and also targeting a protein with no enzymatic activity, which have been part of a curative strategy for HCV.